|
KMID : 0360319940260010009
|
|
Journal of Korean Cancer Research Association
1994 Volume.26 No. 1 p.9 ~ p.15
|
|
|
A Phase II Study of Combined 5-Fluorouracil Etoposide, Doxorubicin, and Cisplatin(F-EAP) in Patients with Advanced Gastric Cancer
|
|
항암화학요법 연구회
|
|
|
Abstract
|
|
|
5-Fluorouracil(5-FU), as a single agent, has a modest but reproducible activity against gastric cancer and continuous infusion of 5-FU is associated with less myelosuppresion. It has been reported that combination of etoposide, doxorubicin, and
cisplatin(EAP) was very active in advanced gastric carcinoma with an overall response rate of 64% including 21% complete response from the German investigators. A phase Ⅱstudy of the combination of 5-FU infusion, etoposide, doxorubicin and
cisplatin(F-EAP), which regimen has been demonstrated to have the different mechanisms of action and synergism between each of drugs in vitro and in vivo, was performed in attempts to evaluate the antitumor activity in patients with advanced
gastric
cancer.
Fifty-five previously untreated patients with surgically unreasectable or metastatic advanced gastric adenocarcinoma were treated with 5-FU(800mg/㎡, days 2, 3, and 4), etoposide(70mg/㎡, days 2, 3, and 4), doxorubicin(30mg/㎡, day 1), and
cisplatin(60mg/㎡, day 1) repeated every 28 days.
Objective responses were observed in 14 of 47(30%) evaluable patients, and the median duration of response was 21 weeks (13~60+). The median survival time of 47 evaluable patients was 40 weeks(16~62). F-EAP therapy was associated with mild
myelosuppression. The common non-hematologic toxicities were nausea/vomiting(94%), mucositis(32%), peripheral neuropathy (15%), and infection (11%), but the majority of these toxicities were mild to moderate and well tolerated.
These results suggest that F-EAP regimen has a modest antitumor activity in terms of response rate and duration of response, and is relatively well tolerated in advanced gastric cancer.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|